A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular Disease
Atherosclerosis · Cardiovascular Disease · Hypercholesterolemia
What this study involves
The registry says this study is recruiting. Individual locations may have different availability.
- Study type
- Interventional
- Phase
- Phase 2
- Age range
- 18 years - 70 years
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 175 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their arteries or are at high risk of developing it.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Established atherosclerotic cardiovascular disease (ASCVD) and/or at a high risk of ASCVD
Exclusion Criteria:
- History of confirmed or suspected homozygous familial hypercholesterolemia (HoFH)
- Chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
Treatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Random assignment
- Masking
- Double masked
VERVE-102 Dose 1
Participants will receive a single dose of VERVE-102 intravenously (IV)
Drug: VERVE-102
VERVE-102 Dose 2
Participants will receive a single dose of VERVE-102 IV
Drug: VERVE-102
VERVE-102 Dose 3
Participants will receive a single dose of VERVE-102 IV
Drug: VERVE-102
Placebo
Participants will receive a single dose of placebo IV
Drug: Placebo
VERVE-102 DRUG
Administered IV
Placebo DRUG
Administered IV
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
Percent Change from Baseline in LDL-C
Time frame: Baseline, Day 90
Not reported in this registry record.
Secondary measures
Percent Change from Baseline in LDL-C
Time frame: Baseline to End of Study (up to Day 365)
Not reported in this registry record.
Percent Change from Baseline in Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Time frame: Baseline to End of Study (up to Day 365)
Not reported in this registry record.
Percent Change from Baseline Total Cholesterol
Time frame: Baseline to End of Study (up to Day 365)
Not reported in this registry record.
Percent Change from Baseline in Non-High-Density Lipoprotein Cholesterol (non-HDL-C)
Time frame: Baseline to End of Study (up to Day 365)
Not reported in this registry record.
Percent Change from Baseline in Apolipoprotein B
Time frame: Baseline to End of Study (up to Day 365)
Not reported in this registry record.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (1)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
1 locations
Epic Medical ResearchDeSoto, Texas, United StatesRecruiting
Study team and timeline
- Lead sponsor
- Verve Therapeutics, Inc.
- Study start
- Sep 24, 2026 Actual
- Primary completion
- 2028-08 Estimated
- Study completion
- 2030-03 Estimated
- First posted
- Sep 24, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026